Outi Kuittinen

Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study

Kuitunen, Hanne K; Rönkä, Aino LK; Sonkajärvi, Eila M; Isokangas, Juha-Matti; Pyörälä, Marja; Palosaari, Kari AA; Jokimäki, Anna S; Partanen, Anu E; Littow, Harri J; Vakkala, Merja A; Jantunen, Esa J; Huttunen, Mirja E; Marin, Katja J; Aromaa-Häyhä, Annikki MK; Auvinen, Päivi K; Selander, Tuomas; Puhakka, Inka K; Kuittinen, Outi M. 2023. Cancers. 15:

CD34(+) Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients

Turunen, Antti Samuli; Kuittinen, Outi; Kuitunen, Hanne; Vasala, Kaija; Penttila, Karri; Harmanen, Minna; Keskinen, Leena; Mantymaa, Pentti; Pelkonen, Jukka; Varmavuo, Ville; Jantunen, Esa; Partanen, Anu. 2023. Transfusion medicine and hemotherapy. [Epub ahead of print 23 Aug 2023]:

Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas

Sorigue, Marc; Kuittinen, Outi. 2023. Cancers. 15:

Follikulaarisen lymfooman muuttuva hoito

Aromaa-Häyhä, Annikki; Auvinen, Päivi; Marin, Katja; Prusila, Roosa; Jokelainen, Otto; Kuittinen, Outi. 2023. Duodecim. 139: 117-125

Lymfoomien patologisanatominen diagnostiikka

Kuittinen, Outi; Aromaa-Häyhä, Annikki; Böhm, Jan; Hämäläinen, Kirsi; Jyrkkiö, Sirkku; Karjalainen-Lindsberg, Marja-Liisa; Leppä, Sirpa; Pollari, Marjukka; Vaittinen, Samuli; Vasala, Kaija; Vornanen, Martine; Kauppila, Saila. 2023. Duodecim. 139: 107-116

Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events

Jokimäki, Anna; Hietala, Henna; Lemma, Jasmiini; Karhapää, Hanna; Rintala, Anna; Kaikkonen, Jari-Pekka; Sunela, Kaisa; Boman, Eva; Jukkola, Arja; Tiainen, Satu; Seppälä, Jan; Rönkä, Aino; Hakkarainen, Heikki; Kärnä, Aarno; Iivanainen, Sanna; Koivunen, Jussi; Auvinen, Päivi; Hernberg, Micaela; Kuusisto, Milla; Selander, Tuomas; Kuittinen, Outi. 2023. Cancer immunology immunotherapy. 72: 3337-3347

R-bendamustine in the treatment of nodular lymphocyte predominant Hodgkin lymphoma-An extended follow-up

Vuolio, Tero; Kuittinen, Outi; Vayrynen, Juha P; Teppo, Hanna-Riikka; Prusil, Roosa EI; Ramet, Maria; Kuitunen, Hanne; Paloneva, Timo; Kuusisto, Milla EL. 2023. British journal of haematology. 202: e24-e26

The Transcription Factor Twist1 Has a Significant Role in Mycosis Fungoides (MF) Cell Biology: An RNA Sequencing Study of 40 MF Cases

Häyrinen, Marjaana J; Kiiskilä, Jenni; Ranki, Annamari; Väkevä, Liisa; Barton, Henry J; Kuusisto, Milla EL; Porvari, Katja; Kuitunen, Hanne; Haapasaari, Kirsi-Maria; Teppo, Hanna-Riikka; Kuittinen, Outi. 2023. Cancers. 15:

Vitamin C boosts DNA demethylation in TET2 germline mutation carriers

Taira, Aurora; Palin, Kimmo; Kuosmanen, Anna; Välimäki, Niko; Kuittinen, Outi; Kuismin, Outi; Kaasinen, Eevi; Rajamäki, Kristiina; Aaltonen, Lauri A.. 2023. Clinical epigenetics. 15: . 7

Chronic Cutaneous Disorders Are Associated with a More Favorable Disease Presentation and Outcome in Patients with Hodgkin Lymphoma

Marin, Katja; Auvinen, Päivi; Kuitunen, Hanne; Kuittinen, Outi. 2022. Oncology research and treatment. 45: 241-246

FDG‐PET/CT‐guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma

Rajamäki, Aino; Kuitunen, Hanne; Sorigue, Marc; Kokkonen, Salla‐Maarit; Kuittinen, Outi; Sunela, Kaisa. 2022. Cancer medicine. 2023; 12: 407-411

Link between disease status at 24 months and mortality in follicular lymphoma

Rajamäki, Aino; Hujo, Mika; Sund, Reijo; Prusila, Roosa E. I.; Kuusisto, Milla E. L.; Kuitunen, Hanne; Jantunen, Esa; Mercadal, Santiago; Sorigue, Marc; Sancho, Juan‐Manuel; Kuittinen, Outi; Sunela, Kaisa. 2022. British journal of haematology. 199: 458-462

Mortality among patients with low‐grade follicular lymphoma: A binational retrospective analysis

Rajamäki, Aino; Hujo, Mika; Sund, Reijo; Prusila, Roosa E. I.; Kuusisto, Milla E. L.; Kuitunen, Hanne; Jantunen, Esa; Mercadal, Santiago; Sorigue, Marc; Sancho, Juan‐Manuel; Sunela, Kaisa; Kuittinen, Outi. 2022. Cancer. 128: 2474-2482

Physiological instability is linked to mortality in primary central nervous system lymphoma: A case–control fMRI study

Poltojainen, Valter; Kemppainen, Janette; Keinänen, Nina; Bode, Michaela; Isokangas, Juha‐Matti; Kuitunen, Hanne; Nikkinen, Juha; Sonkajärvi, Eila; Korhonen, Vesa; Tuovinen, Timo; Järvelä, Matti; Huotari, Niko; Raitamaa, Lauri; Kananen, Janne; Korhonen, Tommi; Tetri, Sami; Kuittinen, Outi; Kiviniemi, Vesa. 2022. Human brain mapping. 43: 4030-4044

Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis

Puhakka, Inka; Kuitunen, Hanne; Jäkälä, Pekka; Sonkajärvi, Eila; Turpeenniemi-Hujanen, Taina; Rönkä, Aino; Selander, Tuomas; Korhonen, Miika; Kuittinen, Outi. 2022. Bmc cancer. 22: . 236

Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020

Harmanen, Minna; Hujo, Mika; Sund, Reijo; Sorigue, Marc; Khan, Madiha; Prusila, Roosa; Klaavuniemi, Tuula; Kari, Esa; Jantunen, Esa; Sunela, Kaisa; Rajamäki, Aino; Alanne, Erika; Kuitunen, Hanne; Sancho, Juan‐Manuel; Jukkola, Arja; Rönkä, Aino; Kuittinen, Outi. 2022. British journal of haematology. 2023; 201: 64-74

Blood Brain Barrier Disruption eli BBBD-hoito aivolymfooman hoidossa - anestesiologit osana moniammatillista hoitotiimiä

Vakkala, Merja; Huttunen, Elina; Kuittinen, Outi; Kuitunen, Hanne; Isokangas, Juha-Matti; Palosaari, Kari; Sonkajärvi, Eila . 2021. Finnanest. 54: 385-388

Blood Graft and Outcome After Autologous Stem Cell Transplantation in Patients With Primary Central Nervous System Lymphoma

Partanen, Anu; Kuittinen, Outi; Turunen, Antti; Valtola, Jaakko; Pyörälä, Marja; Kuitunen, Hanne; Vasala, Kaija; Kuittinen, Taru; Mäntymaa, Pentti; Pelkonen, Jukka; Jantunen, Esa; Varmavuo, Ville. 2021. Journal of hematology. 10: 246-254

Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma

Ollikainen, Riina K; Kotkaranta, Pyry H; Kemppainen, Janette; Teppo, Hanna-Riikka; Kuitunen, Hanne; Pirinen, Risto; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi; Kuusisto, Milla EL. 2021. Leukemia & lymphoma. 62: 2151-2160

Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months

Rajamäki, Aino; Sunela, Kaisa; Prusila, Roosa EI; Kuusisto, Milla EL; Mercadal, Santiago; Selander, Tuomas; Kuitunen, Hanne; Pollari, Marjukka; Jantunen, Esa; Nystrand, Ilja; Sancho, Juan-Manuel; Sorigue, Marc; Kuittinen, Outi. 2021. Leukemia & lymphoma. 62: 1639-1647

Incidence and clinicopathological features of Follicular T-cell lymphoma in Finland; a population-based immunohistochemical study

Kiiskilä, Jenni; Uotila, Pyry; Haapasaari, Kirsi-Maria; Kauppila, Saila; Teppo, Hanna-Riikka; Kuusisto, Milla EL; Lemma, Siria; Turpeenniemi-Hujanen, Taina; Vornanen, Martine; Eray, Mine; Kuittinen, Outi. 2021. Human pathology. 117: 79-87

Interim and end-of-treatment PET-CT suffers from high false-positive rates in DLBCL: Biopsy is needed prior to treatment decisions

Tokola, Susanna; Kuitunen, Hanne; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi. 2021. Cancer medicine. 10: 3035-3044

Robustness and pragmatism of the evidence supporting the European Society for Medical Oncology guidelines for the diagnosis, treatment and follow-up of follicular lymphoma

Sorigue, Marc; Kuittinen, Outi. 2021. Expert review of hematology. 14: 655-668

Testis-Specific Thioredoxins TXNDC2, TXNDC3, and TXNDC6 Are Expressed in Both Testicular and Systemic DLBCL and Correlate with Clinical Disease Presentation

Chan, Mikko C; Savela, Janette; Ollikainen, Riina K; Teppo, Hanna-Riikka; Miinalainen, Ilkka; Pirinen, Risto; Kuitunen, Hanne; Kari, Esa JM; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi; Kuusisto, Milla EL. 2021. Oxidative medicine and cellular longevity. 2021: 8026941

Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study

Turunen, Antti; Valtola, Jaakko; Partanen, Anu; Ropponen, Antti; Kuittinen, Outi; Kuitunen, Hanne; Vasala, Kaija; Ågren, Lasse; Penttilä, Karri; Keskinen, Leena; Savolainen, Eeva-Riitta; Pyörälä, Marja; Kuittinen, Taru; Selander, Tuomas; Mäntymaa, Pentti; Pelkonen, Jukka; Jantunen, Esa; Varmavuo, Ville. 2020. Leukemia & lymphoma. 61: 2082-2092

Autologous stem cell transplantation in peripheral T-cell lymphoma: better mobilization of blood CD34 + cells is associated with improved survival

Partanen, A; Turunen, A; Valtola, J; Pyörälä, M; Vasala, K; Kuittinen, O; Kuitunen, H; Penttilä, K; Kuittinen, T; Mäntymaa, P; Pelkonen, J; Varmavuo, V Jantunen, E. 2020. Leukemia & lymphoma. 61: 3027-3029

CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter Goa study

Turunen, Antti; Partanen, Anu; Valtola, Jaakko; Ropponen, Antti; Siitonen, Timo; Kuittinen, Outi; Kuitunen, Hanne; Putkonen, Mervi; Sankelo, Marja; Keskinen, Leena; Savolainen, Eeva-Riitta; Pyörälä, Marja; Kuittinen, Taru; Silvennoinen, Raija; Penttilä, Karri; Sikiö, Anu; Vasala, Kaija; Mäntymaa, Pentti; Pelkonen, Jukka; Varmavuo, Ville; et al.. 2020. Transfusion. 60: 1519-1528

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

Eskelund, Christian Winther; Dimopoulos, Kostas; Kolstad, Arne; Glimelius, Ingrid; Räty, Riikka; Gjerdrum, Lise Mette Rahbek; Sonnevi, Kristina; Josefsson, Pär; Nilsson-Ehle, Herman; Bentzen, Hans HN; Fagerli, Unn Merete; Kuittinen, Outi; Haaber, Jacob; Niemann, Carsten Utoft; Pedersen, Lone Bredo; Larsen, Maria Torp; Geisler, Christian Hartmann; Hutchings, Martin; Jerkeman, Mats; Grønbæk, Kirsten. 2020. HemaSphere. 2021; 5: e510

Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma

Kuitunen, H; Kaprio, E; Karihtala, P; Makkonen, V; Kauppila, S; Haapasaari, KM; Kuusisto, M; Jantunen, E; Turpeenniemi-Hujanen, T; Kuittinen, O. 2020. Annals of hematology. 99: 1823-1831

Lymfoomahoitojen jälkeiset pitkäaikaishaitat, niiden ehkäisy ja seuranta

Sunela Kaisa, Leppä Sirpa, Kuittinen Outi, Tinkanen Helena, Tuohinen Suvi, Schmitt Florence, Korkeila Eija; Suomen Lymfoomaryhmä. 2020. Duodecim. 136: 2373 - 2381

Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

Partanen, Anu; Turunen, Antti; Valtola, Jaakko; Pyörälä, Marja; Vasala, Kaija; Kuittinen, Outi; Kuitunen, Hanne; Penttilä, Karri; Keskinen, Leena; Kuittinen, Taru; Mäntymaa, Pentti; Pelkonen, Jukka; Varmavuo, Ville; Jantunen, Esa. 2020. Transfusion. 2021; 61: 516-525

Prognostic significance of Twist, ZEB1 and Slug in peripheral T-cell lymphomas

Uotila, PM; Lemma, SA; Haapasaari, KM; Porvari, K; Skarp, S; Soini, Y; Jantunen, E; Turpeenniemi-Hujanen, T; Kuittinen, O. 2020. Hematology. 25: 241-246

Significance of bulky mass and residual tumor - Treated with or without consolidative radiotherapy - To the risk of relapse in DLBCL patients

Tokola, Susanna; Kuitunen, Hanne; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi. 2020. Cancer medicine. 9: 1966-1977

Thioredoxin-1 as a Biological Predictive Marker for Selecting Diffuse Large B-cell Lymphoma Patients for Etoposide-Containing Treatment

Kari, Esa Jarkko Mikael; Kuusisto, Milla Elvi Linnea; Honkavaara, Päivi; Hakalahti, Anna; Haapasaari, Kirsi-Maria; Bloigu, Risto; Karihtala, Peeter; Teppo, Hanna-Riikka; Pirinen, Risto; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi. 2020. European journal of haematology. 105: 156-163

Incidence of solid cancer in patients with follicular lymphoma

Sorigue, M; Prusila, REI; Jauhiainen, J; Mercadal, S; Postila, A; Salmi, P; Tanhua, T; Tikkanen, S; Kakko, S; Kuitunen, H; Pollari, M; Nystrand, I; Kuusisto, MEL; Vasala, K; Jantunen, E; Korkeila, E; Karihtala, P; Sancho, JM; Turpeenniemi-Hujanen, T; Kuittinen, O. 2019. Acta oncologica. 58: 1564-1569

Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP

Kari, E; Teppo, HR; Haapasaari, KM; Kuusisto, MEL; Lemma, A; Karihtala, P; Pirinen, R; Soini, Y; Jantunen, E; Turpeenniemi-Hujanen, T; Kuittinen, O. 2019. Journal of clinical pathology. 72: 316-321

Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma

Kari, EJM; Kuusisto, MEL; Böhm, J; Haapasaari, KM; Teppo, HR; Karihtala, P; Hakalahti, A; Turpeenniemi-Hujanen, T; Kuittinen, O. 2019. Anticancer research. 39: 4925-4931

Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma

Sorigue, M; Bishton, M; Domingo-Domenech, E; McMillan, A; Prusila, R; García, O; Kuusisto, M; Condom, M; Tapia, G; Ribera, JM; Kuittinen, O; Fox, CP; Sancho, JM. 2019. Leukemia & lymphoma. 60: 2524-2531

Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era

Prusila, REI; Sorigue, M; Jauhiainen, J; Mercadal, S; Postila, A; Salmi, P; Tanhua, T; Tikkanen, S; Kakko, S; Kuitunen, H; Pollari, M; Nystrand, I; Kuusisto, MEL; Vasala, K; Jantunen, E; Korkeila, E; Karihtala, P; Sancho, JM; Turpeenniemi-Hujanen, T; Kuittinen, O. 2019. British journal of haematology. 187: 364-371

Twist and Zeb1 expression identify Mycosis fungoides patients with low risk of disease progression

Häyrinen, MJ; Uotila, PM; Sahi, H; Haapasaari, KM; Teppo, HR; Soini, Y; Lapela, M; Vasala, K; Turpeenniemi-Hujanen, T; Ranki, A; Kuusisto, MEL; Kuittinen, O. 2019. Journal of the european academy of dermatology and venereology. 2020; 34: e95-e98

Case report: Chemotherapy in conjunction with blood-brain barrier disruption for a patient with germ cell tumor with multiple brain metastases

Knuutinen, O; Kuitunen, H; Alahuhta, S; Isokangas, J-M; Sonkajärvi, E; Turpeenniemi-Hujanen, T; Kuittinen, O. 2018. Clinical genitourinary cancer. 16: e993-e996

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP

Peroja, P; Pedersen, M; Mantere, T; Nørgaard, P; Peltonen, J; Haapasaari, KM; Böhm, J; Jantunen, E; Turpeenniemi-Hujanen, T; Rapakko, K; Karihtala, P; Soini, Y; Vasala, K; Kuittinen, O. 2018. Scientific reports. 8: 14814

R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma

Prusila, Roosa Enni Inkeri; Haapasaari, Kirsi-Maria; Marin, Katja; Pollari, Marjukka; Soini, Ylermi; Vornanen, Martine; Karjalainen-Lindsberg, Marja-Liisa; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi. 2018. Acta oncologica. 57: 1265-1267

Treatment of Diffuse Large B-cell Lymphoma in Elderly Patients: Replacing Doxorubicin with either Epirubicin or Etoposide (VP-16)

Prusila, Roosa; Peroja, Pekka; Jantunen, Esa; Turpeenniemi-Hujanen, Taina; Kuittinen Outi. 2018. Hematological oncology. 2019; 37: 136-142

Tutkimusryhmät

Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study

CD34(+) Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients

Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas

Follikulaarisen lymfooman muuttuva hoito

Lymfoomien patologisanatominen diagnostiikka

Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events

R-bendamustine in the treatment of nodular lymphocyte predominant Hodgkin lymphoma-An extended follow-up

The Transcription Factor Twist1 Has a Significant Role in Mycosis Fungoides (MF) Cell Biology: An RNA Sequencing Study of 40 MF Cases

Vitamin C boosts DNA demethylation in TET2 germline mutation carriers

Chronic Cutaneous Disorders Are Associated with a More Favorable Disease Presentation and Outcome in Patients with Hodgkin Lymphoma

FDG‐PET/CT‐guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma

Link between disease status at 24 months and mortality in follicular lymphoma

Mortality among patients with low‐grade follicular lymphoma: A binational retrospective analysis

Physiological instability is linked to mortality in primary central nervous system lymphoma: A case–control fMRI study

Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis

Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020

Blood Brain Barrier Disruption eli BBBD-hoito aivolymfooman hoidossa - anestesiologit osana moniammatillista hoitotiimiä

Blood Graft and Outcome After Autologous Stem Cell Transplantation in Patients With Primary Central Nervous System Lymphoma

Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma

Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months

Incidence and clinicopathological features of Follicular T-cell lymphoma in Finland; a population-based immunohistochemical study

Interim and end-of-treatment PET-CT suffers from high false-positive rates in DLBCL: Biopsy is needed prior to treatment decisions

Robustness and pragmatism of the evidence supporting the European Society for Medical Oncology guidelines for the diagnosis, treatment and follow-up of follicular lymphoma

Testis-Specific Thioredoxins TXNDC2, TXNDC3, and TXNDC6 Are Expressed in Both Testicular and Systemic DLBCL and Correlate with Clinical Disease Presentation

Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study

Autologous stem cell transplantation in peripheral T-cell lymphoma: better mobilization of blood CD34 + cells is associated with improved survival

CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter Goa study

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma

Lymfoomahoitojen jälkeiset pitkäaikaishaitat, niiden ehkäisy ja seuranta

Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

Prognostic significance of Twist, ZEB1 and Slug in peripheral T-cell lymphomas

Significance of bulky mass and residual tumor - Treated with or without consolidative radiotherapy - To the risk of relapse in DLBCL patients

Thioredoxin-1 as a Biological Predictive Marker for Selecting Diffuse Large B-cell Lymphoma Patients for Etoposide-Containing Treatment

Incidence of solid cancer in patients with follicular lymphoma

Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP

Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma

Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma

Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era

Twist and Zeb1 expression identify Mycosis fungoides patients with low risk of disease progression

Case report: Chemotherapy in conjunction with blood-brain barrier disruption for a patient with germ cell tumor with multiple brain metastases

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP

R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma

Treatment of Diffuse Large B-cell Lymphoma in Elderly Patients: Replacing Doxorubicin with either Epirubicin or Etoposide (VP-16)